Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas D James

Showing results (191-200 of 198) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 198 results.
The Lancet. Oncology|July 10, 2025
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocolSilke Gillessen, Laura Murphy, Nicholas D James, et al.
The Lancet. Oncology|May 4, 2023
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocolGerhardt Attard, Laura Murphy, Noel W Clarke, et al.
JNCI Cancer Spectrum|July 25, 2022
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled TrialNicholas D James, Fiona C Ingleby, Noel W Clarke, et al.
International Journal of Cancer|April 12, 2022
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)Nicholas D James, Noel W Clarke, Adrian Cook, et al.
European Urology|July 3, 2026
Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) DiagnosticsStefano Fanti, Fabio Turco, Bertrand Tombal, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2023
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022Silke Gillessen, Alberto Bossi, Ian D Davis, et al.
European Urology|December 9, 2022
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022Silke Gillessen, Alberto Bossi, Ian D Davis, et al.
European Urology|October 11, 2024
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)Silke Gillessen, Fabio Turco, Ian D Davis, et al.
Pageof 20

Showing results (191-200 of 198) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 198 results.
The Lancet. Oncology|July 10, 2025
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocolSilke Gillessen, Laura Murphy, Nicholas D James, et al.
The Lancet. Oncology|May 4, 2023
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocolGerhardt Attard, Laura Murphy, Noel W Clarke, et al.
JNCI Cancer Spectrum|July 25, 2022
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled TrialNicholas D James, Fiona C Ingleby, Noel W Clarke, et al.
International Journal of Cancer|April 12, 2022
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)Nicholas D James, Noel W Clarke, Adrian Cook, et al.
European Urology|July 3, 2026
Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) DiagnosticsStefano Fanti, Fabio Turco, Bertrand Tombal, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2023
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022Silke Gillessen, Alberto Bossi, Ian D Davis, et al.
European Urology|December 9, 2022
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022Silke Gillessen, Alberto Bossi, Ian D Davis, et al.
European Urology|October 11, 2024
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)Silke Gillessen, Fabio Turco, Ian D Davis, et al.
Pageof 20